Conveners
Ovarian cancer (PARTII)
- Clemens Decristoforo (Department of Nuclear Medicine, Medical University Innsbruck)
- Samer Ezziddin (Saarland University Hospital, Homburg)
-
Ms Francesca Borgna (1Center for Radiopharmaceutical Sciences, Paul Scherrer Institute, Switzerland)01/05/2019, 09:00Invited
Ovarian cancer represents the most common cause of gynecological cancer death with a 5-year relative survival rate of 29% for patients diagnosed at a metastasized stage (1). The development of new treatment options is urgently needed to treat patients with refractory disease and platinum-resistance (1).
Go to contribution page
The folate receptor (FR) is overexpressed on the cell surface of a variety of tumors... -
Prof. Vicky Caveliers (UZ Brussel - VUB)01/05/2019, 09:30Preclinical research and development of new radiopharmaceuticalsInvited
Approximately, 10-30% of ovarian cancers have an amplification of the human epidermal growth factor receptor type 2 (HER2) gene or overexpression of its protein product, while it is present at low levels in normal tissues. HER2 is a 185 kDa transmembrane protein that belongs to the HER family of tyrosine kinase receptors. Although controversial, recent studies have confirmed that HER2...
Go to contribution page -
Ms Sophia Pells (University of Manchester (GB), National Physical Laboratory (GB)), Dr Nick Calvert (The Christie NHS Foundation Trust,), Thomas Elias Cocolios (KU Leuven - IKS), Mr Kristof Dockx (KU Leuven (BE)), Simon Thomas Stegemann (KU Leuven), Ulli Koester (Institut Laue-Langevin (FR)), Ben Pietras (University of Manchester), Mr Emlyn Price (The University of Manchester, The Christie NHS Foundation Trust), Dr Sean Collins (The National Physical Laboratory), Dr Ana Denis-Bacelar (The National Physical Laboratory), Mr Andrew Fenwick (The National Physical Laboratory), Ms Kelley Ferreira (andrew.fenwick@npl.co.uk), Dr David Hamilton (The Christie NHS Foundation Trust), Dr Kerttuli Helariutta (University of Helsinki), Dr Peter Ivanov (The National Physical Laboratory), Ellen Helen Ulrika Jakobsson (Helsinki Institute of Physics (FI)), Karl Johnston (CERN), Dr John Keightley (The National Physical Laboratory), Dr Christopher Oldfield (The Christie NHS Foundation Trust, The University of Manchester), Ms Emma Page (The University of Manchester, The Christie NHS Foundation Trust), Dr Ben Russell (The National Physical Laboratory), Juliana Schell (Institut Fur Materialwissenschaft Universität Duisburg-Essen (D), Dr Jill Tipping (The Christie NHS Foundation Trust), Mr Ben Webster (The National Physical Laboratory, University of Surrey), Dr Jill L. Wevrett (The National Physical Laboratory, Royal Surrey County Hospital)01/05/2019, 10:00Preclinical research and development of new radiopharmaceuticalsOral
There has been increasing interest in four radioisotopes of terbium with the potential for use in nuclear medicine: 161Tb emits therapeutic beta and Auger particles; 155Tb emits gamma-rays suited to Single-Photon Emission Computed Tomography (SPECT); 152Tb emits positrons suitable for Positron Emission Tomography (PET); and 149Tb emits alpha particles suitable for therapy. Their identical...
Go to contribution page -
Dr Grigory Karateev (EPFL)01/05/2019, 10:35Preclinical research and development of new radiopharmaceuticalsMEDICIS-Promed ESRs
Molecular imaging affords valuable information about biological processes at the molecular and cellular levels within complex living organisms and can help in earlier diagnostics of various diseases. Optical imaging modalities such as fluorescence imaging play a key role for preclinical research. Furthermore, new fluorescence imaging tools have a potential for clinical translation.
Go to contribution page
In this... -
Nina Pil Fredericia (Hevesy Laboratory, DTU-Nutech, Technical University of Denmark, Roskilde, Denmark)01/05/2019, 10:55Preclinical research and development of new radiopharmaceuticalsOral
Auger electron emitters are promising candidates for targeted radionuclide therapy. They decay by internal conversion or electron capture, resulting in Auger cascades with the emission of several low energy (eV-keV) electrons. The multiplicity of electrons combined with their short range (nm-μm) results in a high local energy deposition density near the decay site. Decays happening close to...
Go to contribution page -
Ms Alexandra Litvinenko (UNIGE), Ms Andrea Grotzky (UNIGE)01/05/2019, 11:15Preclinical research and development of new radiopharmaceuticalsMEDICIS-Promed ESRs
Ovarian cancer is the fifth most lethal cancer among women. Early detection is highly warranted in order to optimize therapy, and improve the overall prognosis. However, technologies for early detection of ovarian cancer are currently lacking.
Go to contribution page
Here, we describe the development of a new dual imaging probe for ovarian cancer. This imaging probe is based on folate as targeting moiety. Our probe...